Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer

Breast

Volumn 23, Issue 1, 2014, Pages 88-93

  Wu, San gang ^a   He, Zhen yu ^b   Zhou, Juan ^a   Sun, Jia yuan ^b   Li, Feng yan ^b   Lin, Qin ^a   Guo, Ling ^b   Lin, Huan xin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Breast cancer; CA15 3; CEA; Prognosis

Indexed keywords

ANTHRACYCLINE; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHINESE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

BREAST CANCER; CA15-3; CEA; PROGNOSIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AXILLA; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84890873105     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.11.003     Document Type: Article

References (30)

1. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61(6):409-418.
2. Li J., Zhang B.N., Fan J.H., Pang Y., Zhang P., Wang S.L., et al. Anation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer 2011, 11:364.
3. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
4. Soerjomataram I., Louwman M.W., Ribot J.G., Roukema J.A., Coebergh J.W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107(3):309-330.
5. Molina R., Augé J.M., Escudero J.M., Filella X., Zanon G., Pahisa J., et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010, 31(3):171-180.
6. Park B.W., Oh J.W., Kim J.H., Park S.H., Kim K.S., Kim J.H., et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008, 19(4):675-681.
7. Lumachi F., Basso S.M., Brandes A.A., Pagano D., Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res 2004, 24(5B):3221-3224.
8. Molina R., Filella X., Zanon G., Pahisa J., Alicarte J., Munoz M., et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003, 23(2A):1043-1050.
9. Molina R., Auge J.M., Farrus B., Zanón G., Pahisa J., Muñoz M., et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem 2010, 56(7):1148-1157.
10. Samy N., Ragab H.M., El Maksoud N.A., Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark 2010, 6(2):63-72.
11. Gold P., Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. JExp Med 1965, 121:439-462.
12. Benchimol S., Fuks A., Jothy S., Beauchemin N., Shirota K., Stanners C.P. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989, 57(2):327-334.
13. Duffy M.J., Evoy D., McDermott E.W. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010, 411(23-24):1869-1874.
14. Molina R., Barak V., van Dalen A., Duffy M.J., Einarsson R., Gion M., et al. Tumor markers in Breast Cancer European Group on tumor markers recommendations. Tumour Biol 2005, 26(6):281-293.
15. Marić P., Ozretić P., Levanat S., Oresković S., Antunac K., Beketić-Oresković L. Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol 2011, 35(1):241-247.
16. Hou M.F., Chen Y.L., Tseng T.F., Lin C.M., Chen M.S., Huang C.J., et al. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 1999, 5(9):520-528.
17. Clinton S.R., Beason K.L., Bryant S., Johnson J.T., Jackson M., Wilson C., et al. Acomparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum 2003, 39:408-414.
18. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25(33):5287-5312.
19. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
20. Houssami N., Macaskill P., von Minckwitz G., Marinovich M.L., Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012, 48(18):3342-3354.
21. Lee J.S., Park S., Park J.M., Cho J.H., Kim S.I., Park B.W. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 2013, 24(5):1225-1231.
22. Duffy M.J., Duggan C., Keane R., Hill A.D., McDermott E., Crown J., et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004, 50(3):559-563.
23. Kumpulainen E.J., Keskikuru R.J., Johansson R.T. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002, 76(2):95-102.
24. Ebeling F.C., Schmitt U.M., Untch M., Nagel D., Fateh-Moghadam A., Stieber P., et al. Tumour markers CEA and CA 15-3 as prognostic factors in breast cancer - univariate and multivariate analysis. Anticancer Res 1999, 19(4A):2545-2550.
25. Cañizares F., Sola J., Pérez M., Tovar I., De Las Heras M., Salinas J., et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001, 22(5):273-281.
26. Brenner B., Siris N., Rakowsky E., Fenig E., Sulkes A., Lurie H. Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer 2002, 87(12):1404-1410.
27. Uehara M., Kinoshita T., Hojo T., Akashi-Tanaka S., Iwamoto E., Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008, 13(5):447-451.
28. Ebeling F.G., Stieber P., Untch M., Nagel D., Konecny G.E., Schmitt U.M., et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002, 86(8):1217-1222.
29. Gion M., Boracchi P., Dittadi R., Biganzoli E., Peloso L., Mione R., et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002, 38(9):1181-1188.
30. National Comprehensive Cancer Network [Web page] National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology, breast cancer. Version 1 2011, Available at:, [cited April 10 2013]. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.